Neoadjuvant pembrolizumab-carboplatin-paclitaxel in locally advanced squamous cell carcinoma of the oral cavity: A case report and literature review
Head and neck cancers are being diagnosed more frequently in elderly patients and at advanced stages. In these cases, standard treatment methods are often not feasible due to patient frailty and malnutrition. A few trials have demonstrated the safety and effectiveness of immune checkpoint inhibitors...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-09-01
|
| Series: | Oral Oncology Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772906024004424 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841553672830451712 |
|---|---|
| author | Abdulrahman Hesham Fawaz AlOtaibi D. David Kim Yousef Alshamrani Joao Hyppolito Katie Jubala |
| author_facet | Abdulrahman Hesham Fawaz AlOtaibi D. David Kim Yousef Alshamrani Joao Hyppolito Katie Jubala |
| author_sort | Abdulrahman Hesham |
| collection | DOAJ |
| description | Head and neck cancers are being diagnosed more frequently in elderly patients and at advanced stages. In these cases, standard treatment methods are often not feasible due to patient frailty and malnutrition. A few trials have demonstrated the safety and effectiveness of immune checkpoint inhibitors (ICIs) as neoadjuvant therapy for locally advanced oral cancer. We present the case of a 51-year-old male patient who had locally advanced oral cavity cancer that was treated with the combination of pembrolizumab and weekly carboplatin and paclitaxel. This treatment resulted in a major pathological response, leading to a significant reduction in tumor size and allowing for surgical treatment. In addition, the patient remains free of locoregional disease nine months after the surgery. Clinical trials are essential to investigate the viability of this potentially less toxic and more convenient combined therapy in patients with advanced squamous cell carcinoma of the oral cavity. |
| format | Article |
| id | doaj-art-6c3a42c922504b33916ffde90eb09f0f |
| institution | Kabale University |
| issn | 2772-9060 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Oral Oncology Reports |
| spelling | doaj-art-6c3a42c922504b33916ffde90eb09f0f2025-01-09T06:16:52ZengElsevierOral Oncology Reports2772-90602024-09-0111100596Neoadjuvant pembrolizumab-carboplatin-paclitaxel in locally advanced squamous cell carcinoma of the oral cavity: A case report and literature reviewAbdulrahman Hesham0Fawaz AlOtaibi1D. David Kim2Yousef Alshamrani3Joao Hyppolito4Katie Jubala5Corresponding author.; Department of Oral and Maxillofacial Surgery, Head and Neck Oncology and Microvascular Reconstructive Surgery, LSU Health Science Center Shreveport, 1501 Kings Highway, PO Box 33932, Shreveport, LA, 71130-3932, USADepartment of Oral and Maxillofacial Surgery, Head and Neck Oncology and Microvascular Reconstructive Surgery, LSU Health Science Center Shreveport, 1501 Kings Highway, PO Box 33932, Shreveport, LA, 71130-3932, USADepartment of Oral and Maxillofacial Surgery, Head and Neck Oncology and Microvascular Reconstructive Surgery, LSU Health Science Center Shreveport, 1501 Kings Highway, PO Box 33932, Shreveport, LA, 71130-3932, USADepartment of Oral and Maxillofacial Surgery, Head and Neck Oncology and Microvascular Reconstructive Surgery, LSU Health Science Center Shreveport, 1501 Kings Highway, PO Box 33932, Shreveport, LA, 71130-3932, USADepartment of Oral and Maxillofacial Surgery, Head and Neck Oncology and Microvascular Reconstructive Surgery, LSU Health Science Center Shreveport, 1501 Kings Highway, PO Box 33932, Shreveport, LA, 71130-3932, USADepartment of Oral and Maxillofacial Surgery, Head and Neck Oncology and Microvascular Reconstructive Surgery, LSU Health Science Center Shreveport, 1501 Kings Highway, PO Box 33932, Shreveport, LA, 71130-3932, USAHead and neck cancers are being diagnosed more frequently in elderly patients and at advanced stages. In these cases, standard treatment methods are often not feasible due to patient frailty and malnutrition. A few trials have demonstrated the safety and effectiveness of immune checkpoint inhibitors (ICIs) as neoadjuvant therapy for locally advanced oral cancer. We present the case of a 51-year-old male patient who had locally advanced oral cavity cancer that was treated with the combination of pembrolizumab and weekly carboplatin and paclitaxel. This treatment resulted in a major pathological response, leading to a significant reduction in tumor size and allowing for surgical treatment. In addition, the patient remains free of locoregional disease nine months after the surgery. Clinical trials are essential to investigate the viability of this potentially less toxic and more convenient combined therapy in patients with advanced squamous cell carcinoma of the oral cavity.http://www.sciencedirect.com/science/article/pii/S2772906024004424Neoadjuvant immunotherapyPembrolizumabPaclitaxelCarboplatinOral cancer |
| spellingShingle | Abdulrahman Hesham Fawaz AlOtaibi D. David Kim Yousef Alshamrani Joao Hyppolito Katie Jubala Neoadjuvant pembrolizumab-carboplatin-paclitaxel in locally advanced squamous cell carcinoma of the oral cavity: A case report and literature review Oral Oncology Reports Neoadjuvant immunotherapy Pembrolizumab Paclitaxel Carboplatin Oral cancer |
| title | Neoadjuvant pembrolizumab-carboplatin-paclitaxel in locally advanced squamous cell carcinoma of the oral cavity: A case report and literature review |
| title_full | Neoadjuvant pembrolizumab-carboplatin-paclitaxel in locally advanced squamous cell carcinoma of the oral cavity: A case report and literature review |
| title_fullStr | Neoadjuvant pembrolizumab-carboplatin-paclitaxel in locally advanced squamous cell carcinoma of the oral cavity: A case report and literature review |
| title_full_unstemmed | Neoadjuvant pembrolizumab-carboplatin-paclitaxel in locally advanced squamous cell carcinoma of the oral cavity: A case report and literature review |
| title_short | Neoadjuvant pembrolizumab-carboplatin-paclitaxel in locally advanced squamous cell carcinoma of the oral cavity: A case report and literature review |
| title_sort | neoadjuvant pembrolizumab carboplatin paclitaxel in locally advanced squamous cell carcinoma of the oral cavity a case report and literature review |
| topic | Neoadjuvant immunotherapy Pembrolizumab Paclitaxel Carboplatin Oral cancer |
| url | http://www.sciencedirect.com/science/article/pii/S2772906024004424 |
| work_keys_str_mv | AT abdulrahmanhesham neoadjuvantpembrolizumabcarboplatinpaclitaxelinlocallyadvancedsquamouscellcarcinomaoftheoralcavityacasereportandliteraturereview AT fawazalotaibi neoadjuvantpembrolizumabcarboplatinpaclitaxelinlocallyadvancedsquamouscellcarcinomaoftheoralcavityacasereportandliteraturereview AT ddavidkim neoadjuvantpembrolizumabcarboplatinpaclitaxelinlocallyadvancedsquamouscellcarcinomaoftheoralcavityacasereportandliteraturereview AT yousefalshamrani neoadjuvantpembrolizumabcarboplatinpaclitaxelinlocallyadvancedsquamouscellcarcinomaoftheoralcavityacasereportandliteraturereview AT joaohyppolito neoadjuvantpembrolizumabcarboplatinpaclitaxelinlocallyadvancedsquamouscellcarcinomaoftheoralcavityacasereportandliteraturereview AT katiejubala neoadjuvantpembrolizumabcarboplatinpaclitaxelinlocallyadvancedsquamouscellcarcinomaoftheoralcavityacasereportandliteraturereview |